Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma

NCT01454089 is registered in ClinicalTrials.gov with Achieve Life Sciences as lead sponsor.

NCT NCT01454089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01454089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma
Lead sponsor
Achieve Life Sciences
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2011
Completion date
November 30, 2014
Enrollment
183 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic bladder cancer, urinary tract neoplasms, urologic neoplasms